6 citations
,
December 2013 in “Journal of Dermatological Science” This study found that Taiwanese women with alopecia may have a significantly higher risk of developing thyroid cancer compared to those without alopecia.
January 2022 in “Clinical Cases in Dermatology” This case report details a 26-year-old woman with diffuse hair loss following treatment for thyroid cancer, subsequent thyroidectomy, and development of hypothyroidism and hypoparathyroidism managed with thyroxin.
1 citations
,
July 2014 in “International Journal of Dermatology” A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.
188 citations
,
October 2014 in “Thyroid” This study found that dabrafenib was well tolerated and led to durable responses in patients with BRAF-mutant differentiated thyroid carcinoma, with a median progression-free survival of 11.3 months.
39 citations
,
June 2019 in “Frontiers in Endocrinology” This study reported that while both sorafenib and lenvatinib may require dose modifications due to adverse events in treating advanced or metastatic thyroid cancers, key differences in side effect profiles were observed.